With its 10 million new cases and 1.5 million deaths annually, TB remains a priority global health problem. It is therefore essential that professionals are aware of the burden that this disease imposes on humanity, the strategies and solutions for the challenges that TB entails. The WHO’s End TB Strategy and UN General Assembly resolutions call on governments to commit to its implementation, relying not only on national programmes and the public health sector, but seeking to pursue a multi-sectorial effort that may foster TB elimination on a global scale.
Educational aims
- Build knowledge of healthcare professionals and other professionals on epidemiological traits of TB on a global scale;
- Have the confidence to devise and develop strategies that are able to lessen the burden of TB;
- Understand the premises and topics underlying the End TB Strategy and which efforts could be undertaken in order to compromise with the targets established by the WHO
Topics/Programme
- Epidemiology of TB (estimates of incidence, mortality, drug-resistant TB estimates, TB/HIV);
- International targets and progress towards them;
- New challenges and strategies to move forward;
- Global End TB Strategy to face the challenge;
- Q&A
Learning outcomes
Following the webinar, participants will be able to:
- Understand the global impact of TB, through epidemiological concepts;
- Transpose epidemiological concepts of TB to clinical practice;
- Understand the global challenges of TB;
- Develop strategies to lessen the burden of TB;
- Understand the premises underlying the End TB Strategy and its implications for clinical practice.
Format
Panel discussion divided into two parts (of approximately 30 min each):
- Presentation on the global burden of TB (Mario Raviglione)
- Open discussion and Q&A (moderated by chairs)
CME credit
An application for accreditation of this webinar has been made to the European Board for Accreditation in Pneumology (EBAP) for 1 CME credit per 1-hour attendance. If accredited, the CME credit will be granted upon attendance of at least 60 minutes during the live webinar only.
What is a webinar?
A webinar closely simulates a lecture-based teaching experience. The speaker can interact with the audience, just as in a classroom setting. During the webinar, you will be asked to share your opinion on issues related to the topic using interactive polls.
All participants will be able to hear the lecturer and see the slides throughout the presentation. As a participant you will be able to pose questions or discuss ideas with the other participants via the text chat facility and the speaker will respond to the questions via the microphone.
Login guidelines
More information will be communicated in due course.
- Please log in to the webinar 20 minutes before it is scheduled to commence. If you have any technical difficulties whilst trying to log in or during the session please contact e-learning@ersnet.org.
- Check Central European Time.
- To achieve the best quality, we recommend to avoid downloading anything from the internet during your connection to the lecture and stopping all other programmes.
- Please also ensure that your audio settings are not set to mute and adjust the volume to a comfortable level.
About UNITE4TB
UNITE4TB is a public-private partnership with representation from academic institutions, small- and medium-sized enterprises (SMEs), public organisations, and pharmaceutical companies. The 7-year, €185 million project aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active Tuberculosis (TB) treatment regimens for drug-resistant and -sensitive TB. For more information, visit the consortium website: www.unite4TB.org
Funding
The UNITE4TB project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research. For further information: www.imi.europa.eu
Disclaimer
This communication reflects the author’s view. Neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
